logo
Goodbye, dad bod: Weight loss medications are changing fathers' physiques — and their relationships with their kids.

Goodbye, dad bod: Weight loss medications are changing fathers' physiques — and their relationships with their kids.

Yahooa day ago

Neal Bland has done Ironman competitions and marathons. He's given countless personal training sessions over the course of his life and has always prided himself on staying in shape, especially given that obesity runs in his family. But by age 52, time and genetics had begun to catch up with Bland (who asked that we not use his real last name for privacy reasons).
His blood pressure and blood sugar were climbing, his body mass index was hovering in the low 30s, and his joints were aching. Then, during a photo shoot with his wife last year, the photographer told Bland he 'looked good for a dad bod.' Bland knew the photographer had 'meant it as a compliment,' he tells Yahoo Life, 'but it really stuck.' He was still maintaining a rigorous diet and exercise regimen at the time, but it wasn't working for him. So, in March of 2024, he started on the GLP-1 medication tirzepatide. He's lost 45 pounds in a phase of his life he's dubbed his 'dad bod reboot.'
Let's be clear: There's nothing wrong with a dad bod. In fact, the expectation for men to have chiseled abs — at any point, but especially in middle and older age — can be harmful. But for the 38% of American dads who are obese, their bodies may be putting them at risk of type 2 diabetes, heart disease and other potentially life-threatening medical conditions. Some of these fathers have started taking GLP-1 weight loss medications, a decision that can bring about not just changes to their 'bods' and health indicators, but also to their lives as parents.
We spoke to some of them about what it's like to be a dad, minus their former bods.
Thirty-seven-year-old father of two Noah Wiggins is taking his nursing board exams and looking forward to beginning his new career in health care. 'But I looked in the mirror and thought, I can't expect patients to be healthy and maintain a healthy weight if I can't,' he tells Yahoo Life. Plus, Wiggins loves coaching his children's sports teams, but he found himself getting winded and sore when he tried to demonstrate athletic skills for the kids. While he could shed pounds for a time with the help of various diets, he couldn't maintain a healthy weight long-term. So Wiggins talked to his own health care provider, who agreed that GLP-1 medication could be a good option for him.
He started taking Zepbound in January 2024. The medication, along with the support of his two children, has helped him lose more than 80 pounds since then. 'As I started to lose weight and get more active, they started making comments and encouraging me to make healthy food choices … without judgment,' says Wiggins. His daughter, who is about to turn 16, has been especially vocal, keeping Wiggins accountable when he picks up an unhealthy snack or tries to flake on going to the gym. 'I've had to fight the urge to say, 'I'm the parent, I'll go when I want to,'' says Wiggins. But ultimately, he's grateful for the tough-loving support from his kids. 'I think it's been a growing moment for them and for me,' he says. Wiggins's children have also noticed that he has more energy and can just be more fully present for them.
Despite his progress, Wiggins still struggles with his body image. Like others that Wiggins has spoken to within the GLP-1 community, he half-expected that once the scale reached a certain number, he would feel satisfied with his body and appearance. 'But I don't know anyone who actually hits that number and feels like that,' he says. 'I look in the mirror and am happy with how I look and especially how I feel, but body dysmorphia is a real thing, and a lot of times you don't know you have it until you've lost weight.' At his lowest weight, Wiggins was tempted to lose another 20 pounds to make his reflection match the idealized version of himself in his mind, but he knew that would have put him below a healthy weight.
That's when Wiggins realized that it wasn't about losing more weight. He needed to make a conscious effort to improve his mental health and confidence to help him feel content in his own skin. It's an important lesson that he wants his children to learn: how to 'be comfortable in your body, but balance that with good health,' Wiggins says. He's pushed himself to talk more openly with his kids about his own journey toward striking that balance. 'The best thing to do was just have more conversations with them about all of that, and they'll actually take the lead on those conversations once you start them.'
Twenty years ago, when Ryan Rasmussen and his wife, AnnaLyn, were young newlyweds, they wanted desperately to start a family. After three years of trying, AnnaLyn got pregnant with quadruplets. But tragedy struck: None of the four babies survived more than about an hour after birth. The Rasmussens managed to pick up the pieces of their shattered hearts and eventually went on to have four children, born individually. But even as someone moves on, grief can linger in the body, wreaking havoc. For Rasmussen, the loss of his newborns quietly ate at him and, in turn, Rasmussen now recognizes he ate to cope with his grief. He reached nearly 300 pounds, he told Yahoo Life for our series On My Weigh.
For those intervening 20 years, Rasmussen tried the Atkins diet and various other low-carb eating plans. He'd lose a little weight, then gain back as much or more. In the meantime, his family stayed active and went on ski trips. 'Annalyn is a marathon runner, and she's kept [the kids] in shape, but I think they've probably worried about me,' says Rasmussen. He tried to join their athletic activities, but skiing and hiking were hard on his overburdened joints. Two of his sisters, who also struggled with their weight, found success with GLP-1 medications. Impressed with their progress, Rasmussen tried the new class of weight loss drugs too. Within a year, he dropped 80 pounds. 'Being there for my family was the goal,' he says.
Not only can Rasmussen now join the family ski trips, but hiking and spending time outdoors are day-to-day ways he bonds with his kids. His weight loss 'has definitely allowed us as a family to do more healthy activities,' Rasmussen says. Plus, his good habits have rubbed off on his children. Desserts, once a staple, are reserved for special occasions, and the household's midnight snacking has all but disappeared.
Rasmussen's new body has also allowed him to get back in touch with his fashion sense. 'I like to look good and dress well, but when you're big, [that's] difficult,' he says. Now that he's lost weight, 'being able to dress with purpose in the morning has probably been one of the best things for me and my mental health,' says Rasmussen. And he's not the only one who's noticed his new look. One of his daughter's friends used the viral 'hear me out' cake trend on TikTok as an excuse to show some appreciation for Rasmussen. 'She said, 'hear me out, but Charlie's dad is attractive,'' Rasmussen explains. 'But [Charlie] was a good sport, she laughed about it.'
Bland's now adult children grew up knowing him as the ultra-fit dad, who was always on the go for his job as a pharmaceutical researcher, or hitting the gym to train for his next big event. But he was always fighting against his genetics. 'I come from a long line of fluffy people,' Bland says.
He spent his own childhood watching his mother constantly watch her weight. Despite avoiding smoking and drinking and maintaining a reasonably healthy diet, she eventually had to have both of her knees and one hip replaced and also suffered a stroke, 'all of which can be attributed to [extra] weight on your frame,' says Bland. Recognizing his family's propensity to obesity was part of what drove Bland to be so disciplined. 'But my genetics eventually outran my lifestyle,' he says.
Even with the same routines in place, Bland gained weight in his early 50s, saw his A1C and blood pressure rise, and had inflammation in his hips and knees. And Bland admits that vanity was also a factor. The shirtless man in his vacation photos no longer looked like the version of himself he expected to see. 'I gained about 35 pounds in 10 years; it was the classic 'man-o-pause,'' he says.
Though he didn't meet the clinical qualifications for brand-name GLP-1 medications, Bland tried compounded tirzepatide, suspecting that it would not only help him keep weight off but also reduce the inflammation in his joints. Once he started the medication, 'it was literally like somebody flipped a switch,' says Bland. The food noise (constant, intrusive thoughts about food) disappeared. He no longer ate just because he was bored. The joint pain was barely noticeable, and his workout recovery time improved. He also started to look more like himself in gym selfies.
Bland didn't initially tell his children that he was taking GLP-1 medications. But one of his adult sons noticed that Bland was looking pretty shredded in some of his photos; in fact, he was a bit concerned. He told his father, 'You've lost so much weight and went from really fluffy to really not. Are you sure you're not ... taking PEDs,' meaning performance-enhancing drugs, recalls Bland. Though Bland, now 53, has been taking testosterone replacement therapy for years, that and the GLP-1 have allowed him to return to the weight and energy levels of his younger years. And he's now switched to a very low maintenance dose of tirzepatide to make sure he doesn't lose too much weight. 'It's been a little bit of a return to what they were used to when they were kids,' he says of his new — or, maybe more accurately, restored — bod. 'And I feel like I'm back to the person that my wife married,' Bland adds.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Most Chronic Hepatitis B Diagnoses in US Are Late
Most Chronic Hepatitis B Diagnoses in US Are Late

Medscape

timean hour ago

  • Medscape

Most Chronic Hepatitis B Diagnoses in US Are Late

More than 75% of chronic hepatitis B diagnoses in the United States occur late — within 2 years before or after the onset of a liver complication — highlighting the need for improved screening to prevent poor outcomes. METHODOLOGY: Late diagnosis of chronic hepatitis B represents a missed opportunity to intervene early and prevent liver-related complications. Researchers conducted a retrospective analysis of the Truven MarketScan database (2007 to 2021) to estimate the prevalence of late diagnosis of chronic hepatitis B in the US and associated liver complications. Eligible patients had chronic hepatitis B diagnosis and at least 12 months of insurance coverage prior to the first liver complication (cirrhosis, hepatocellular carcinoma [HCC], or liver transplant). A diagnosis was defined as late if it occurred within 2 years before or after the first liver complication, and non-late if was made more than 2 years before the complication. TAKEAWAY: Of 2608 patients included (mean age, 54.83 years; 29.7% women), 76.6% had a late diagnosis of chronic hepatitis B; among these, 44.5% were diagnosed at or within 6 months of their first liver complication, and 75.5% lacked a documented visit to a medical provider prior to their first liver complication. Among those diagnosed > 36 months after the first liver complication, 46% already had another liver disease. Despite treatment advances, the rate of late diagnosis remained stable between 2010 (78.8%) and 2019 (89.3%; P for trend = . 438). for trend 438). Among patients with a late diagnosis, 91.0% had cirrhosis, 81.5% had decompensated cirrhosis, 30.8% developed HCC, and 14.4% underwent liver transplant. Independent predictors of late diagnosis included male sex, alcohol use, and having Preferred Provider Organization (PPO) or Health Maintenance Organization/PPO hybrid insurance. IN PRACTICE: 'Our study suggests that the majority of [hepatitis B virus] diagnoses in the United States are likely incidental from the work-up of a liver complication. These patients can be seen as 'missed opportunities' for treatment and intervention to prevent disease progression and adverse hepatic outcomes,' the authors wrote. SOURCE: This study was led by Michael Le and Joanne K. Liu, Stanford University Medical Center, Stanford, California. It was published online in Alimentary Pharmacology & Therapeutics . LIMITATIONS: This study excluded uninsured individuals and those covered by government insurance (eg, Medicaid), potentially underrepresenting higher-risk populations. Reliance on claims data may have affected the accuracy of diagnosis rates. Data on race, ethnicity, and foreign-born status were unavailable, preventing analysis of these important factors. DISCLOSURES: The authors received no specific funding for this work. No conflicts of interest were disclosed by the authors.

Adverse Events Post-Colonoscopy Rise With Age but Are Rare
Adverse Events Post-Colonoscopy Rise With Age but Are Rare

Medscape

time2 hours ago

  • Medscape

Adverse Events Post-Colonoscopy Rise With Age but Are Rare

Although adverse event rates within 30 days after surveillance colonoscopy increase with age, peaking among patients aged 76-85 years, they remain infrequent, occurring in < 1% of procedures. METHODOLOGY: Guidelines recommend surveillance colonoscopy for patients with precancerous adenomas due to an increased colorectal cancer risk but lack recommendations for stopping surveillance after the age of 75 years despite older adults experiencing increased comorbidities. Researchers analyzed data from 84,172 surveillance colonoscopies performed from 2010 to 2019 within a large integrated US healthcare system. Participants (59.5% men; 66.4% White individuals), aged 45-85 years, had a prior adenoma and were followed up to 30 days post-procedure for adverse events. Outcomes included emergency department visits, hospitalizations, and deaths due to specific conditions (eg, colonic perforation and stroke), cardiovascular conditions, or any cause. Logistic regression was used to assess the association between age and adverse event risk, adjusting for various factors. TAKEAWAY: Adverse events occurred in < 1% of procedures, with gastrointestinal bleeding being the most common. Adverse event rates increased with age, with the highest rates observed in patients aged 76-85 years (69.6 events per 10,000 procedures), particularly for gastrointestinal bleeding (39.2 events per 10,000 procedures) and stroke (18.3 events per 10,000 procedures). Patients aged 76-85 years had significantly higher odds of adverse events than younger age groups in unadjusted analyses, but these odds were attenuated after adjusting for covariates. Significant risk factors for adverse events across all age groups included anticoagulant use, higher comorbidity scores, polypectomy, and advanced neoplasia detection during surveillance colonoscopy. IN PRACTICE: 'The findings suggest that the decision to perform colonoscopy surveillance after age 75 should be individualized based on patient preference, prior colonoscopy findings and procedure quality, comorbidities, and medication usage, rather than age alone,' the authors wrote. SOURCE: This study was led by Jeffrey K. Lee, MD, Kaiser Permanente Northern California in Oakland, California. It was published online in Clinical Gastroenterology and Hepatology . LIMITATIONS: Findings may not be generalizable, as all participants were insured and had access to comprehensive care. The observational design lacked a noncolonoscopy comparison group, making it difficult to attribute adverse events directly to the procedure. Limited numbers of certain adverse events resulted in wide CIs, and potential confounders like polyp size or number and sedation type were not adjusted for. DISCLOSURES: This study was conducted within the National Cancer Institute-funded Population-based Research to Optimize the Screening Process consortium and supported by a career development grant from the same agency. The authors reported no relevant conflicts of interest.

Nivolumab Plus Chemotherapy Improves Survival in Lung Cancer
Nivolumab Plus Chemotherapy Improves Survival in Lung Cancer

Medscape

time3 hours ago

  • Medscape

Nivolumab Plus Chemotherapy Improves Survival in Lung Cancer

Adding nivolumab to neoadjuvant chemotherapy significantly improved 5-year overall survival among patients with resectable non-small cell lung cancer (NSCLC), according to findings from a phase 3 trial presented at the recent American Society of Clinical Oncology (ASCO) 2025 annual meeting. The survival benefit was more pronounced in patients who achieved a pathologic complete response or a presurgery clearance of circulating tumor DNA (ctDNA). METHODOLOGY: The phase 3 CheckMate 816 trial has shown that compared with neoadjuvant chemotherapy alone, nivolumab plus chemotherapy improvespathologic complete response rates and event-free survival in patients with stage IB-IIIA resectable NSCLC. Based on these findings, this regimen was approved for this patient population in the US, EU, and other places. compared with neoadjuvant chemotherapy alone, nivolumab plus chemotherapy improvespathologic complete response rates and event-free survival in patients with stage IB-IIIA resectable NSCLC. Based on these findings, this regimen was approved for this patient population in the US, EU, and other places. Researchers are now reporting the final, prespecified analysis of overall survival. In the trial, 358 patients with stage IB-IIIA resectable NSCLC were randomly assigned to receive either nivolumab plus platinum-based chemotherapy or platinum-based chemotherapy alone every 3 weeks for three cycles. Surgery was performed within 6 weeks of completing neoadjuvant treatment. Postoperative adjuvant chemotherapy, radiotherapy, or both were permitted. Primary endpoints were event-free survival and pathologic complete response. Overall survival was the key secondary endpoint. The median follow-up duration was 68.4 months. TAKEAWAY: The 5-year overall survival rate was 65.4% with nivolumab plus chemotherapy vs 55.0% with chemotherapy alone. Nivolumab plus chemotherapy reduced the risk for death by 28% (hazard ratio [HR], 0.72; P = .048). = .048). Among patients who received the combination therapy, the 5-year overall survival rate was 95.3% for those who achieved a pathological complete response vs 55.7% for those who did not. Overall, 24% of patients in the nivolumab group achieved a pathological complete response vs only 2.2% in the chemotherapy group. ctDNA clearance before surgery was a strong prognostic indicator, regardless of treatment. At 5 years, overall survival was 75.0% among patients with ctDNA clearance vs 52.6% in those without (HR for death, 0.38 in the nivolumab group and 0.39 in the chemotherapy-only group). The combination therapy was associated with consistent survival benefits across disease stage and PDL-1 expression levels. The 5-year lung cancer-specific survival rate was 74.9% with nivolumab plus chemotherapy vs 65.1% with chemotherapy alone (HR, 0.65). No new safety concerns emerged, and there were no new deaths related to a trial treatment. IN PRACTICE: 'In this trial, we found that the use of neoadjuvant nivolumab plus chemotherapy resulted in significantly longer overall survival than chemotherapy alone, along with long-term benefit regarding event-free survival,' the authors wrote. 'These findings support the hypothesis that neoadjuvant chemoimmunotherapy can have a profound impact on the course of a patient's life when paired with the curative potential of surgical resection.' SOURCE: This study, led by Patrick M. Forde, MB, BCh, PhD, Trinity St. James's Cancer Institute, Trinity College Dublin, Dublin, Ireland, was published online in The New England Journal of Medicine and presented at ASCO. LIMITATIONS: Although the overall survival with nivolumab plus chemotherapy achieved statistical significance, the margin was narrow. Additionally, several subgroups in the exploratory analyses were too small for adequate statistical comparison, requiring cautious interpretation of these results. Black patients were underrepresented, which may have affected the generalizability of the findings. DISCLOSURES: This study was funded by Bristol Myers Squibb. Five authors declared being employees of Bristol Myers Squibb, with some holding stock or stock options with the company. Several authors declared working as consultants or having other ties with various sources including Bristol Myers Squibb.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store